Clinical data | |
---|---|
Other names | RG-1662; RO5186582 |
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG |
|
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C21H20FN3O5S |
Molar mass | 445.47 g·mol−1 |
3D model (JSmol) | |
| |
|
Basmisanil (INNTooltip International Nonproprietary Name; developmental codes RG-1662 and RO5186582) is a highly selective inverse agonist/negative allosteric modulatorofα5 subunit-containing GABAA receptors which is under development by Roche for the treatment of cognitive impairment associated with Down syndrome.[1][2][3] As of June 2016, it is no longer studied for this purpose.[4] It underwent a clinical trial for cognitive impairment in patients with schizophrenia.[5]
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |